Direct%252525252525252525252525252525252520oral%252525252525252525252525252525252520anticoagulants

# Direct Oral Anticoagulants (DOACs) ## Overview Direct oral anticoagulants (DOACs) are a class of anticoagulant medications that directly inhibit specific coagulation factors. They offer predictable pharmacokinetics and pharmacodynamics, eliminating the need for routine laboratory monitoring compared to warfarin. ## Primary Indications * **Non-valvular atrial fibrillation (NVAF):** Prevention of stroke and systemic embolism. * **Venous thromboembolism (VTE):** Treatment and prevention of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE). * **Prophylaxis following hip or knee replacement surgery.** ## Adult Dosing Dosing is dependent on the specific agent, indication, and patient factors (e.g., renal function, weight). * **Apixaban (Eliquis):** * NVAF: 5 mg twice daily. Reduced to 2.5 mg twice daily if two or more criteria are met: age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dL. * VTE Treatment/Recurrence: 10 mg twice daily for 7 days, followed by 5 mg twice daily. * VTE Prophylaxis (post-op): 2.5 mg twice daily, starting 12-24 hours after surgery. * **Rivaroxaban (Xarelto):** * NVAF: 20 mg once daily. Reduced to 15 mg once daily for patients with creatinine clearance (CrCl) 15-49 mL/min. * VTE Treatment/Recurrence: 15 mg once daily for 21 days, followed by 20 mg once daily. * VTE Prophylaxis (post-op): 10 mg once daily, starting 6-8 hours after surgery. * **Edoxaban (Savaysa):** * NVAF: 60 mg once daily. Reduced to 30 mg once daily for patients with CrCl 15-50 mL/min or concomitant use of P-glycoprotein inhibitors (e.g., verapamil, quinidine). * VTE Treatment/Recurrence: 60 mg once daily, following at least 5 days of parenteral anticoagulant therapy. * **Dabigatran (Pradaxa):** * NVAF: 150 mg twice daily. Reduced to 110 mg twice daily for patients aged 70-80 years, or with CrCl 30-50 mL/min, or on verapamil. * VTE Treatment/Recurrence: 150 mg twice daily, following at least 5 days of parenteral anticoagulant therapy. ## Pediatric Dosing Pediatric dosing is established for **rivaroxaban** and **apixaban** for select indications. Dosing is weight-based and age-dependent. Refer to specific product labeling or pediatric guidelines for exact dosages. ## Dose Adjustments Dose adjustments are primarily based on **renal function**. Specific criteria for dose reduction exist for apixaban, rivaroxaban, and edoxaban. Consult product monographs for detailed guidance. Hepatic impairment also requires careful consideration, particularly in patients with moderate to severe liver disease. Weight-based dosing adjustments are also critical for pediatric patients. ## Contraindications * Active bleeding. * Known hypersensitivity to the drug. * Conditions with a high risk of clinically significant hemorrhage. * Concomitant use with other anticoagulants (e.g., warfarin, other DOACs, unfractionated heparin unless being converted or for specific indications). ## Adverse Effects The most significant adverse effect is **bleeding**, which can range from minor (bruising, epistaxis) to life-threatening hemorrhage. Other potential adverse effects include dyspepsia (dabigatran), rash, and elevated liver enzymes. ## Key Drug Interactions * **Strong P-glycoprotein (P-gp) and/or Cytochrome P450 3A4 (CYP3A4) inhibitors/inducers:** Can alter DOAC concentrations. Examples include azole antifungals, protease inhibitors, rifampin, carbamazepine, phenytoin. * **Other anticoagulants and antiplatelet agents:** Increased risk of bleeding. * **Nonsteroidal anti-inflammatory drugs (NSAIDs):** Increased risk of bleeding. * **Proton pump inhibitors (PPIs):** May affect absorption of dabigatran. ## Monitoring Routine laboratory monitoring (e.g., INR, aPTT) is **not required** for DOACs. * **Renal function** should be assessed at baseline and periodically as clinically indicated. * **Bleeding risk factors** should be evaluated at initiation and ongoing. * Specific anti-drug **activity assays** are available for some DOACs but are generally reserved for situations where reversal is needed or in severe bleeding cases. ## Clinical Pearls * DOACs offer a more predictable anticoagulant effect compared to warfarin, simplifying management. * **Adherence is crucial.** Missed doses can lead to sub-therapeutic levels and increased thrombotic risk. Patients should be advised on how to manage missed doses (follow specific product guidance or consult prescriber). * **Renal function and drug interactions** are key considerations for dose adjustment and safety. * Reversal agents are available for some DOACs (e.g., idarucizumab for dabigatran, andexanet alfa for apixaban and rivaroxaban) for life-threatening bleeding. * DOACs should be **switched carefully** if transitioning to or from warfarin or other anticoagulants, following specific protocols to avoid periods of over- or under-coagulation. *** **Disclaimer:** This information is intended for healthcare professionals and provides a concise overview. It is not exhaustive. Prescribers should always consult the most current prescribing information, relevant clinical guidelines, and consider individual patient factors before making therapeutic decisions.